Clinical Trials
A New Tool Helps Match Patients with the Right Trials Faster
Fox Trial Finder is a free online tool that helps people with Parkinson's find clinical studies looking for participants. Instead of spending hours searching through medical databases, families can answer a few questions and get matched with studies happening nearby. This makes it easier to explore new treatment options without the usual frustration. *
michaeljfox.orgNew Sensor Device Could Track Medication Levels in Real Time
Researchers at UC San Diego are testing a small sensor that measures levodopa levels in the body without invasive procedures. For families managing medication timing, this could mean fewer guesswork moments and more predictable symptom control. The study is currently recruiting participants. *
clinicaltrials.ucsd.eduStudy Tests Safety of Cell Therapy for Motor Symptoms
A clinical trial at UCSF is evaluating whether injecting dopamine-producing cells is safe for people with Parkinson's. Early results suggest the procedure is well-tolerated, though more research is needed. This approach aims to address the root cause of movement difficulties rather than just masking symptoms. *
clinicaltrials.gov
Breakthrough Treatments
Two New Therapies Move Closer to FDA Approval
Two experimental Parkinson's drugs — tavapadon and bemdaneprocel — have completed Phase 3 trials and are awaiting FDA review. Tavapadon targets motor symptoms with a once-daily pill, while bemdaneprocel uses stem cell-derived dopamine cells. If approved, they would be the first new Parkinson's treatments in years. *
apdaparkinson.orgA Common Supplement Shows Potential for Protecting Brain Cells
N-acetyl-L-leucine, an amino acid already used in Europe for balance disorders, is being studied for its anti-inflammatory effects in Parkinson's. Early trial participants showed reduced brain inflammation and slower symptom progression compared to placebo. A larger study is now underway. *
news.feinberg.northwestern.eduJapan's Conditional Approval of Stem Cell Therapy Opens New Doors
Japan has become the first country to conditionally approve a stem cell-based therapy for Parkinson's disease. The treatment uses donor stem cells to replace lost dopamine-producing neurons. While not yet a cure, it represents a new category of treatment that could eventually slow or halt disease progression. *
michaeljfox.org
Lifestyle Interventions
Exercise Recommendations Updated with New Evidence
The Parkinson's Foundation and the American College of Sports Medicine released updated exercise guidelines, emphasizing that moderate-to-vigorous aerobic exercise — like brisk walking or cycling — improves motor symptoms and quality of life. Experts now recommend at least 150 minutes per week, tailored to each person's abilities. *
parkinson.orgThe PARK-in-Shape Trial: Why Aerobic Exercise Matters
A landmark Dutch study found that people with Parkinson's who did 40 minutes of aerobic exercise three times per week had significantly better motor scores than those who only stretched. Researchers concluded that exercise should be considered a core part of Parkinson's management, alongside medication. *
acsm.orgHow Balance Training Helps Reduce Falls
A systematic review of 45 studies found that balance-specific training — such as tai chi or specialized physiotherapy — reduced fall rates by up to 40% in people with early-to-mid stage Parkinson's. Small, consistent practice at home was as effective as supervised sessions. *
Emerging Research
Scientists Identify a New Drug Target for Slowing Parkinson's
Researchers at Van Andel Institute discovered that blocking a specific protein reduced the spread of alpha-synuclein clumps in cellular models of Parkinson's. These clumps are a hallmark of the disease, and slowing their spread could keep symptoms milder for longer. Drug development is now underway. *
vai.orgInflammation-Reducing Drug Shows Promise in Early Trials
A compound called CTS2444-32 reduced brain inflammation and lowered toxic alpha-synuclein levels in Parkinson's models. Importantly, it did so without affecting normal cellular function — a key safety concern with earlier anti-inflammatory approaches. Human trials are being planned. *
news.fiu.eduFirst-in-Human Study of Gene Silencing for Parkinson's
A new clinical trial is testing whether ALN-SNCA — a gene-silencing drug — is safe and tolerable in people with Parkinson's. The drug aims to reduce production of alpha-synuclein, the protein that forms the clumps seen in Parkinson's brains. Early safety data is expected within a year. *
clinicaltrials.gov
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.